Loading market dashboard
Artelo Biosciences, Inc.
ARTLHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
SOLANA BEACH, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today provided a business update and announced its financial and operational results for the quarter ended March 31, 2026, and outlined upcoming milestones across its portfolio.
SOLANA BEACH, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced details of a strategic partnership with BioAI company ScienceMachine to accelerate the development of its fatty acid-binding protein 5 (FABP5) inhibitor platform. ScienceMachine's platform, which leverages cutting-edge AI agent technology, is built to interrogate large biological datasets in a fraction of the time and cost of traditional methods.
Demonstrates ART26.12's Differentiated Profile as a Promising Pain Treatment Ahead of Planned Multiple Ascending Dose Study This Year
SOLANA BEACH, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical‑stage pharmaceutical company focused on modulating lipid‑signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced that it has received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), the “Equity Rule,” and Listing Rule 5620(a), the “Annual Shareholders Meeting Rule.
SOLANA BEACH, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced the closing of its previously announced private placement of 3,188,407 shares of common stock (or pre-funded warrant in lieu thereof) and warrants to purchase up to 6,376,814 shares of common stock, at a combined purchase price of $3.45 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants.
Artelo Biosciences, Inc. (NASDAQ: ARTL - Get Free Report) saw a large decline in short interest in the month of March. As of March 13th, there was short interest totaling 37,410 shares, a decline of 29.6% from the February 26th total of 53,146 shares. Currently, 6.0% of the company's shares are sold short. Based on an
SOLANA BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 3,188,407 shares of common stock (or pre-funded warrant in lieu thereof) and warrants to purchase up to 6,376,814 shares of common stock, at a combined purchase price of $3.45 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants, in a private placement priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $3.20 per share, will be exercisable upon issuance and will expire five and one-half years from the Effectiveness Date (as defined below). The private placement is expected to close on or about March 30, 2026, subject to the satisfaction of customary closing conditions.
Artelo Biosciences requested the withdrawal of its Registration Statement on Form S-1, initially filed with the U.S. Securities and Exchange Commission on March 20 and declared effective on March 25.
Evaluating Potential to Preserve Muscle Mass Associated with Weight Reduction Announces Preclinical Study Initiation, Patent Filing and Publication of Independent Scientific Research SOLANA BEACH, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced a strategic expansion opportunity for ART27.13 in muscle preservation for patients undergoing glucagon-like peptide-1 (“GLP-1”) receptor agonist therapy.
Three clinical programs, one core molecule, and a capital-efficient strategy position Artelo Biosciences for sustained growth beyond a single indication Three clinical programs, one core molecule, and a capital-efficient strategy position Artelo Biosciences for sustained growth beyond a single indication
ART27.13 is a peripherally selective synthetic cannabinoid.
Biotech and healthcare innovators are advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global ac
BRISTOL, Tenn., March 18, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences (NASDAQ: ARTL) has announced its entry into the ophthalmology space with a fully funded clinical study evaluating ART27.13 in glaucoma patients.
Investigator-sponsored study funded by Glaucoma UK and the HSC R&D Division expands ART27.13's clinical potential into ophthalmology
